drugset / Trial / NCT05456854

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

NCT05456854 ↗

Phase 1 Withdrawn Massachusetts General Hospital
RandomizedCrossoverQuadruple-blindOther

Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp

Timeline

Start
2022-06-03
Primary completion
2024-08-01
Completion
2024-08-01

Outcome

Outcome not reported

Stopped: “Futility”

Drugs

EvaluationDrugModalityDoseRoute
Subject Kisspeptin-10 Peptide — Intravenous

Indications